Literature DB >> 22581855

Leukemia inhibitory factor signaling is required for lung protection during pneumonia.

Lee J Quinton1, Joseph P Mizgerd, Kristie L Hilliard, Matthew R Jones, Candice Y Kwon, Eri Allen.   

Abstract

Lung infections represent a tremendous disease burden and a leading cause of acute lung injury. STAT3 signaling is essential for controlling lung injury during pneumonia. We previously identified LIF as a prominent STAT3-activating cytokine expressed in the airspaces of pneumonic lungs, but its physiological significance in this setting has never been explored. To do so, Escherichia coli was intratracheally instilled into C57BL/6 mice in the presence of neutralizing anti-LIF IgG or control IgG. Anti-LIF completely eliminated lung LIF detection and markedly exacerbated lung injury compared with control mice as evidenced by airspace albumin content, lung liquid accumulation, and histological analysis. Although lung bacteriology was equivalent between groups, bacteremia was more prevalent with anti-LIF treatment, suggestive of compromised barrier function rather than impaired antibacterial defense as the cause of dissemination. Inflammatory cytokine expression was also exaggerated in anti-LIF-treated lungs, albeit after injury had ensued. Interestingly, alveolar neutrophil recruitment was modestly but significantly reduced compared with control mice despite elevated cytokine levels, indicating that inflammatory injury was not a consequence of excessive neutrophilic alveolitis. Lastly, the lung transcriptome was dramatically remodeled during pneumonia, but far more so following LIF neutralization, with gene changes implicating cell death and epithelial homeostasis among other processes relevant to tissue injury. From these findings, we conclude that endogenous LIF facilitates tissue protection during pneumonia. The LIF-STAT3 axis is identified in this study as a critical determinant of lung injury with clinical implications for pneumonia patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581855      PMCID: PMC3370070          DOI: 10.4049/jimmunol.1200256

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

1.  Burden of disease--implications for future research.

Authors:  C M Michaud; C J Murray; B R Bloom
Journal:  JAMA       Date:  2001-02-07       Impact factor: 56.272

Review 2.  Acute lower respiratory tract infection.

Authors:  Joseph P Mizgerd
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

3.  IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia.

Authors:  Shean J Aujla; Yvonne R Chan; Mingquan Zheng; Mingjian Fei; David J Askew; Derek A Pociask; Todd A Reinhart; Florencia McAllister; Jennifer Edeal; Kristi Gaus; Shahid Husain; James L Kreindler; Patricia J Dubin; Joseph M Pilewski; Mike M Myerburg; Carol A Mason; Yoichiro Iwakura; Jay K Kolls
Journal:  Nat Med       Date:  2008-02-10       Impact factor: 53.440

Review 4.  Lung stem cells.

Authors:  Darrell N Kotton; Alan Fine
Journal:  Cell Tissue Res       Date:  2007-09-06       Impact factor: 5.249

5.  TL1A both promotes and protects from renal inflammation and injury.

Authors:  Rafia S Al-Lamki; Jun Wang; Aviva M Tolkovsky; J Andrew Bradley; Jules L Griffin; Sathia Thiru; Eddie C Y Wang; Eleanor Bolton; Wang Min; Paul Moore; Jordan S Pober; John R Bradley
Journal:  J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 10.121

Review 6.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

7.  Alveolar epithelial STAT3, IL-6 family cytokines, and host defense during Escherichia coli pneumonia.

Authors:  Lee J Quinton; Matthew R Jones; Bryanne E Robson; Benjamin T Simms; Jeffrey A Whitsett; Joseph P Mizgerd
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-10       Impact factor: 6.914

Review 8.  The unsolved enigmas of leukemia inhibitory factor.

Authors:  Donald Metcalf
Journal:  Stem Cells       Date:  2003       Impact factor: 6.277

9.  Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.

Authors:  P Ye; F H Rodriguez; S Kanaly; K L Stocking; J Schurr; P Schwarzenberger; P Oliver; W Huang; P Zhang; J Zhang; J E Shellito; G J Bagby; S Nelson; K Charrier; J J Peschon; J K Kolls
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

10.  Gene expression and biological processes influenced by deletion of Stat3 in pulmonary type II epithelial cells.

Authors:  Yan Xu; Machiko Ikegami; Yanhua Wang; Yohei Matsuzaki; Jeffrey A Whitsett
Journal:  BMC Genomics       Date:  2007-12-10       Impact factor: 3.969

View more
  33 in total

Review 1.  Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling.

Authors:  Lee J Quinton; Joseph P Mizgerd
Journal:  Annu Rev Physiol       Date:  2014-08-13       Impact factor: 19.318

2.  Effects of intratracheally instilled laser printer-emitted engineered nanoparticles in a mouse model: A case study of toxicological implications from nanomaterials released during consumer use.

Authors:  Sandra V Pirela; Xiaoyan Lu; Isabelle Miousse; Jennifer D Sisler; Yong Qian; Nancy Guo; Igor Koturbash; Vincent Castranova; Treye Thomas; John Godleski; Philip Demokritou
Journal:  NanoImpact       Date:  2016-01-21

3.  Induction of STAT3-Dependent CXCL5 Expression and Neutrophil Recruitment by Oncostatin-M during Pneumonia.

Authors:  Katrina E Traber; Kristie L Hilliard; Eri Allen; Gregory A Wasserman; Kazuko Yamamoto; Matthew R Jones; Joseph P Mizgerd; Lee J Quinton
Journal:  Am J Respir Cell Mol Biol       Date:  2015-10       Impact factor: 6.914

4.  NLRP3 protein deficiency exacerbates hyperoxia-induced lethality through Stat3 protein signaling independent of interleukin-1β.

Authors:  Yoshiko Mizushina; Koumei Shirasuna; Fumitake Usui; Tadayoshi Karasawa; Akira Kawashima; Hiroaki Kimura; Motoi Kobayashi; Takanori Komada; Yoshiyuki Inoue; Naoko Mato; Hideaki Yamasawa; Eicke Latz; Yoichiro Iwakura; Tadashi Kasahara; Masashi Bando; Yukihiko Sugiyama; Masafumi Takahashi
Journal:  J Biol Chem       Date:  2014-12-29       Impact factor: 5.157

5.  The Lung-Liver Axis: A Requirement for Maximal Innate Immunity and Hepatoprotection during Pneumonia.

Authors:  Kristie L Hilliard; Eri Allen; Katrina E Traber; Kazuko Yamamoto; Nicole M Stauffer; Gregory A Wasserman; Matthew R Jones; Joseph P Mizgerd; Lee J Quinton
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

Review 6.  Integrative Physiology of Pneumonia.

Authors:  Lee J Quinton; Allan J Walkey; Joseph P Mizgerd
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

7.  Respiratory infection and the impact of pulmonary immunity on lung health and disease.

Authors:  Joseph P Mizgerd
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405

8.  Genetic deletion of the Tas2r143/Tas2r135/Tas2r126 cluster reveals that TAS2Rs may not mediate bitter tastant-induced bronchodilation.

Authors:  Ping Lu; Mai K ElMallah; Zeyu Liu; Chan Wu; Jun Chen; Lawrence M Lifshitz; Ronghua ZhuGe
Journal:  J Cell Physiol       Date:  2021-02-08       Impact factor: 6.513

9.  Large scale cytokine profiling uncovers elevated IL12-p70 and IL-17A in severe pediatric acute respiratory distress syndrome.

Authors:  Judith Ju Ming Wong; Herng Lee Tan; Jieliang Zhou; Jan Hau Lee; Jing Yao Leong; Joo Guan Yeo; Yie Hou Lee
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

10.  The molecular pathways underlying host resistance and tolerance to pathogens.

Authors:  Elizabeth J Glass
Journal:  Front Genet       Date:  2012-12-14       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.